Stehman-Breen Catherine 4
4 · Dyne Therapeutics, Inc. · Filed Jul 6, 2022
Insider Transaction Report
Form 4
Stehman-Breen Catherine
Director
Transactions
- Award
Stock Option (right to buy)
2022-07-05+7,222→ 7,222 totalExercise: $5.54Exp: 2030-07-30→ Common Stock (7,222 underlying)
Footnotes (1)
- [F1]The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.